Biohaven Says Potential Neurodegenerative Disease Treatment Failed to Achieve Statistical Significance; Shares Fall Pre-Bell

MT Newswires Live11-25 21:22

Biohaven (BHVN) shares were lower premarket Monday after the biopharmaceutical company said a study of its experimental drug for spinal muscular atrophy did not achieve a "statistically significant difference" compared with placebo and standard of care at 48 weeks.

The company said the experimental treatment "showed clinically meaningful improvements" in motor function for patients in the study.

Biohaven said it intends to accelerate taldefgrobep alpha clinical plans in Q4 and engage with the US Food and Drug Administration on a path forward for the treatment.

Spinal muscular atrophy is a disorder characterized by the loss of motor neurons, atrophy of limb muscles, and muscle weakness that is often fatal.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2486081836?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2024-11-25 21:22","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2486081836","market":"nz","top_or_hot":-1,"title":"Biohaven Says Potential Neurodegenerative Disease Treatment Failed to Achieve Statistical Significance; Shares Fall Pre-Bell","media":"MT Newswires Live","content":"<html><body><p> Biohaven (BHVN) shares were lower premarket Monday after the biopharmaceutical company said a study of its experimental drug for spinal muscular atrophy did not achieve a \"statistically significant difference\" compared with placebo and standard of care at 48 weeks.</p><p>The company said the experimental treatment \"showed clinically meaningful improvements\" in motor function for patients in the study.</p><p>Biohaven said it intends to accelerate taldefgrobep alpha clinical plans in Q4 and engage with the US Food and Drug Administration on a path forward for the treatment.</p><p>Spinal muscular atrophy is a disorder characterized by the loss of motor neurons, atrophy of limb muscles, and muscle weakness that is often fatal.</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Biohaven Says Potential Neurodegenerative Disease Treatment Failed to Achieve Statistical Significance; Shares Fall Pre-Bell</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBiohaven Says Potential Neurodegenerative Disease Treatment Failed to Achieve Statistical Significance; Shares Fall Pre-Bell\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-11-25 21:22 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.mtnewswires.com/><strong>MT Newswires Live</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Biohaven (BHVN) shares were lower premarket Monday after the biopharmaceutical company said a study of its experimental drug for spinal muscular atrophy did not achieve a \"statistically significant ...</p>\n\n<a href=\"https://www.mtnewswires.com/\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LU1093756168.USD","symbol_name":"FRANKLIN K2 ALTERNATIVE STRATEGIES \"A\" (USD) ACC","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2486081836","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2486081836","pubTimestamp":1732540934,"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"Biohaven  shares were lower premarket Monday after the biopharmaceutical company said a study of its experimental drug for spinal muscular atrophy did not achieve a \"statistically significant difference\" compared with placebo and standard of care at 48 weeks.The company said the experimental treatment \"showed clinically meaningful improvements\" in motor function for patients in the study.Biohaven said it intends to accelerate taldefgrobep alpha clinical plans in Q4 and engage with the US Food and Drug Administration on a path forward for the treatment.Spinal muscular atrophy is a disorder characterized by the loss of motor neurons, atrophy of limb muscles, and muscle weakness that is often fatal.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"LU1093756168.USD":"FRANKLIN K2 ALTERNATIVE STRATEGIES \"A\" (USD) ACC","LU1093756325.SGD":"FTIF - Franklin K2 Alt Strat Fd A (acc) SGD-H1","BHVN":"Biohaven Pharmaceutical Holding Co Ltd.","BK4139":"生物科技"},"translate_title":"Biohaven表示，潜在的神经退行性疾病治疗未能达到统计学意义；盘前股价下跌","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"BHVN":0.9},"content_text":"Biohaven (BHVN) shares were lower premarket Monday after the biopharmaceutical company said a study of its experimental drug for spinal muscular atrophy did not achieve a \"statistically significant difference\" compared with placebo and standard of care at 48 weeks.The company said the experimental treatment \"showed clinically meaningful improvements\" in motor function for patients in the study.Biohaven said it intends to accelerate taldefgrobep alpha clinical plans in Q4 and engage with the US Food and Drug Administration on a path forward for the treatment.Spinal muscular atrophy is a disorder characterized by the loss of motor neurons, atrophy of limb muscles, and muscle weakness that is often fatal.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.29.3","shortVersion":"4.29.3","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2486081836"}